Corcept Therapeutics Incorporated has announced the termination of its Distribution Services Agreement with Optime Care, Inc. The agreement, originally dated August 4, 2017 and amended on April 1, 2024, designated Optime as the specialty pharmacy distributor for Korlym® and Corcept's authorized generic mifepristone medication. Corcept delivered notice of termination to Optime on October 10, 2025, with the agreement set to end effective January 8, 2026. Previously, on June 17, 2025, Corcept notified Optime that it would cease to be the exclusive provider of pharmacy services for these medications as of September 15, 2025. The agreement allowed for termination by Corcept for convenience with 90 days' advance notice.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-237834), on October 14, 2025, and is solely responsible for the information contained therein.